ADAM proteases, ErbB pathways and cancer.

Abstract:

:A disintegrin and metalloproteases (ADAMs) are zinc-dependent trans-membrane metalloproteases that shed the extracellular domains of membrane-bound growth factors, cytokines and receptors. Key functions of ADAMs have emerged in ErbB signalling pathways as being sheddases for multiple ErbB ligands. As the ErbB pathway is a validated target for anti-cancer drugs, the upstream activators of ErbB ligands, their sheddases, now enter the spotlight as new drug targets in the ErbB pathway. ADAMs are involved not only in tumour cell proliferation but also in angiogenesis and metastasis. Therefore, strategies targeting ADAMs might be an important complement to existing anti-ErbB approaches.

authors

Zhou BB,Fridman JS,Liu X,Friedman SM,Newton RC,Scherle PA

doi

10.1517/13543784.14.6.591

subject

Has Abstract

pub_date

2005-06-01 00:00:00

pages

591-606

issue

6

eissn

1354-3784

issn

1744-7658

journal_volume

14

pub_type

杂志文章,评审
  • Discontinued drug therapies to treat diabetes in 2014.

    abstract:INTRODUCTION:Available drugs partially attenuate the hyperglycemia characteristic of diabetes. However, successful approaches to treat the root cause or to cure or prevent diabetes remain elusive. Drug discovery and development programs continue to focus on mechanisms that impact specific symptoms of diabetes. In 2014,...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.2015.1058777

    authors: Colca JR

    更新日期:2015-01-01 00:00:00

  • Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy.

    abstract:INTRODUCTION:Aberrant regulation of platelet-derived growth factors (PDGFs) and their receptors (PDGFR) has been shown to be involved in many solid tumors, including breast cancer. PDGFR-α and PDGFR-β expressions were documented in breast cancer and are correlated with tumor aggressiveness and metastasis. Preclinical e...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2014.895323

    authors: Criscitiello C,Gelao L,Viale G,Esposito A,Curigliano G

    更新日期:2014-05-01 00:00:00

  • Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.

    abstract::Introduction: Plasma kallikrein is a  mediator of vascular leakage and inflammation. Activation of plasma kallikrein can induce features of diabetic macular edema (DME) in preclinical models. Human vitreous shows elevated plasma kallikrein levels in patients with DME. Because of the incomplete response of some patient...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2020.1723078

    authors: Bhatwadekar AD,Kansara VS,Ciulla TA

    更新日期:2020-03-01 00:00:00

  • Non-invasive imaging of plaque vulnerability: an important tool for the assessment of agents to stabilise atherosclerotic plaques.

    abstract::Disruption of a vulnerable atherosclerotic plaque is well-recognised as the primary cause of stroke, non-fatal myocardial infarction and sudden cardiac death. Novel therapeutic agents are being developed to stabilise such plaques. The initial evaluation of these drugs would be facilitated by the use of non-invasive im...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.5.693

    authors: Sosnovik DE,Muller JE,Kathiresan S,Brady TJ

    更新日期:2002-05-01 00:00:00

  • Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens.

    abstract:BACKGROUND:Potent new drugs against multidrug-resistant Gram-negative bacteria, namely Pseudomonas aeruginosa and Acinetobacter spp. and pan-drug-resistant Klebsiella pneumoniae, which constitute an increasing medical threat, are almost absent from the future pharmaceutical pipeline. OBJECTIVE:This drug evaluation foc...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.17.5.749

    authors: Poulakou G,Giamarellou H

    更新日期:2008-05-01 00:00:00

  • Potential therapy paradigms for Marfan syndrome.

    abstract::Marfan syndrome is the most common genetic disorder of the connective tissue with an estimated prevalence of 1:10,000. The disease is characterised by manifestations in the cardiovascular, skeletal and ocular systems. The most severe manifestations are those of the cardiovascular system: mitral valve prolapse and dila...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.8.7.983

    authors: Phylactou LA,Kilpatrick MW

    更新日期:1999-07-01 00:00:00

  • Phase II anti-inflammatory and immune-modulating drugs for acute ischaemic stroke.

    abstract:INTRODUCTION:Stroke is the second leading cause of death worldwide and the leading cause of adult neurological disability. Despite advances in stroke unit care, and increasing use of thrombolysis, there remains an urgent need for safe and effective treatments for acute ischaemic stroke. However, this is against a backd...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2015.1020110

    authors: Smith CJ,Denes A,Tyrrell PJ,Di Napoli M

    更新日期:2015-05-01 00:00:00

  • Histone deacetylase inhibitors: discovery and development as anticancer agents.

    abstract::Histone deacetylase (HDAC) inhibitors are a new class of targeted anticancer agents. Several HDAC inhibitors are in clinical trials and have shown significant activity against a spectrum of both haematological and solid tumours at doses that are well tolerated by patients. HDACs and histone acetyltransferases can, by ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.14.12.1497

    authors: Marks PA,Dokmanovic M

    更新日期:2005-12-01 00:00:00

  • Alprostadil infusion in patients with dry age related macular degeneration: a randomized controlled clinical trial.

    abstract:BACKGROUND:Age-related macular degeneration is the leading cause of blindness among elderly individuals in industrialized countries. New drugs and advanced concepts for the treatment of dry AMD (dAMD) are needed. A new approach is the application of intravenous infusions of prostaglandin E1. OBJECTIVE:The aim of this ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1517/13543784.2013.794782

    authors: Augustin AJ,Diehm C,Grieger F,Bentz J

    更新日期:2013-07-01 00:00:00

  • Alpha-lipoic acid, an anti-obesity agent?

    abstract::Obesity shortens life expectancy and is a risk factor for hypertension and Type 2 diabetes. When added to the standard chow of Sprague-Dawley or Otsuka Long-Evans Tokushima Fatty rats, alpha-lipoic acid (0.5% weight/weight) reduced body weight and food intake. Alpha-lipoic acid also increased whole-body energy expendi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.12.1641

    authors: Doggrell SA

    更新日期:2004-12-01 00:00:00

  • Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders.

    abstract::Neuroimmunophilin ligands are a class of compounds that hold great promise for the treatment of nerve injuries and neurological disease. In contrast to neurotrophins (e.g., nerve growth factor), these compounds readily cross the blood-brain barrier, being orally effective in a variety of animal models of ischaemia, tr...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.10.2331

    authors: Gold BG

    更新日期:2000-10-01 00:00:00

  • Prorenin receptor blockers: effects on cardiovascular complications of diabetes and hypertension.

    abstract::When the 'handle region' of the prorenin prosegment interacts with the (pro)renin receptor, the prorenin molecule partially changes the conformation to an enzymatically active state. On the other hand, the receptor triggers its own intracellular signalling pathways independent of the renin-angiotensin system (RAS). Th...

    journal_title:Expert opinion on investigational drugs

    pub_type: 社论,评审

    doi:10.1517/13543784.15.10.1137

    authors: Ichihara A,Kaneshiro Y,Suzuki F

    更新日期:2006-10-01 00:00:00

  • Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas.

    abstract:INTRODUCTION:Soft tissue sarcomas (STS) are a rare and difficult to treat malignancy. Efforts to utilize targeted therapy have been ongoing for the last decade and have resulted in the approval of pazopanib for treatment of advanced disease. Although several other agents have been investigated, the inability to predict...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2015.1076792

    authors: Mohindra N,Agulnik M

    更新日期:2015-01-01 00:00:00

  • Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.

    abstract:INTRODUCTION:Type 2 diabetes is a chronic metabolic disease characterized by persistent hyperglycemia resulting from progressive deficient of insulin in patients with a background of insulin resistance. Current treatment algorithms recommended by American Diabetes Association/The European Association for the Study of D...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1360274

    authors: Tan X,Cao X,Zhou M,Zou P,Hu J

    更新日期:2017-09-01 00:00:00

  • Novel therapies for the prevention of malaria.

    abstract:BACKGROUND:Malaria continues to exact a huge toll on the health of residents of endemic countries. Thus, new approaches to prevention and treatment are needed. OBJECTIVE:To provide an update on novel therapies for the prevention of malaria. METHODS:Systematic MEDLINE search from 1956 to 2008 using the search term 'ma...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780802514039

    authors: Bojang KA

    更新日期:2008-12-01 00:00:00

  • Dawn of Aurora kinase inhibitors as anticancer drugs.

    abstract::With the current standard chemotherapy regimens only approximately 25% of acute myelogenous leukaemia (AML) patients survive > 5 years. Aurora kinases are overexpressed in many human cancers. VX-680 inhibited Aurora-A, -B, -C and the FMS-like tyrosine kinase-3 with apparent inhibitory constants of 0.6, 18, 4.6 and 30 ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.9.1199

    authors: Doggrell SA

    更新日期:2004-09-01 00:00:00

  • Recent advances in the treatment of epithelial ovarian cancer.

    abstract::Ovarian cancer leads to more fatalities than any other form of gynaecological cancer in North America and Europe. Over the last 30 years survival figures have improved somewhat due to improvements in diagnosis, surgery and chemotherapy. Despite these advances, the majority of patients will die from their disease, with...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.10.9.1715

    authors: Harries M,Kaye SB

    更新日期:2001-09-01 00:00:00

  • Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.

    abstract:INTRODUCTION:Pro-protein [corrected] convertase subtilisin kexin (PCSK)-9 is a newly discovered protein involved in intracellular and extracellular regulation of low-density lipoprotein receptor (LDLR) expression. Autosomal dominant activating mutations in PCSK-9 cause familial hypercholesterolaemia whereas inactivatin...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2012.679340

    authors: Wierzbicki AS,Hardman TC,Viljoen A

    更新日期:2012-05-01 00:00:00

  • Fospropofol disodium, a water-soluble prodrug of the intravenous anesthetic propofol (2,6-diisopropylphenol).

    abstract:BACKGROUND:Today, propofol or 2,6-diisopropylphenol is the anesthetic mainly used for monitored anesthetic care sedation and during intravenous anesthesia. The formulation, a lipid macroemulsion, shows several disadvantages. Therefore, during the past years considerable scientific effort has been undertaken to find eit...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780903193063

    authors: Fechner J,Ihmsen H,Jeleazcov C,Schüttler J

    更新日期:2009-10-01 00:00:00

  • Recent developments in the treatment of sepsis.

    abstract::Despite advances in supportive care, septic shock remains a major cause of morbidity and mortality. With the identification of the systemic inflammatory response as a major component in the pathogenesis of the septic shock syndrome, much of the recent work has focused on modulating this response. This includes antiend...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.2.139

    authors: Sharma VK,Dellinger RP

    更新日期:2003-02-01 00:00:00

  • An array of immunotherapeutic strategies for B-cell lymphomas.

    abstract::With FDA approval of monoclonal antibodies (mAb) against the B-cell-specific cell surface molecule CD20, immunotherapy in B-cell non-Hodgkin's-lymphomas (NHL) has gained momentum. Since the first description of the CD20 mAb and its use in a single patient, it has taken more than 20 years to implement this in current t...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.8.12.2059

    authors: Schultze JL

    更新日期:1999-12-01 00:00:00

  • The development of antibody delivery systems to target cancer with highly potent maytansinoids.

    abstract::Improving the tumour selectivity of cytotoxic drugs through conjugation to tumour-reactive monoclonal antibodies may lead to novel, more potent agents for cancer therapy. The maytansinoid drugs are 100- to 1000-fold more cytotoxic in vitro than current clinical anticancer drugs. We recently demonstrated that conjugati...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.2.169

    authors: Liu C,Chari RV

    更新日期:1997-02-01 00:00:00

  • Therapies in development for the treatment of migraine.

    abstract::While oral formulations of agonists at the serotonin (5-HT) receptor subdivisions 5-HT(1B/1D)--the "triptan" class of drugs--dominate the market for migraine therapy and while still more triptans are under development, recent research efforts have also explored other pharmacological avenues, which are mostly based on ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.12.1813

    authors: Mucke H

    更新日期:2002-12-01 00:00:00

  • New antithrombotic drugs on the horizon.

    abstract::Venous and arterial thromboembolism are a major cause for morbidity and mortality. The list of established drugs for the prevention of thrombus formation and embolisation includes heparins, hirudin and derivatives, aspirin, ADP and glycoprotein IIb/IIIa receptor antagonists, as well as vitamin K antagonists. Several l...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.5.781

    authors: Ruef J,Katus HA

    更新日期:2003-05-01 00:00:00

  • Investigations on gossypol: past and present developments.

    abstract::Gossypol has received significant attention as a result of its potential therapeutic application as a male antifertility agent. Furthermore, recent research examining the biological activity of gossypol has revealed a number of other promising lines of enquiry. These have focused on the antitumour, antiviral and antio...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.14.11.1419

    authors: Dodou K,Anderson RJ,Small DA,Groundwater PW

    更新日期:2005-11-01 00:00:00

  • Is everolimus useful in preventing allograft rejection and vasculopathy after heart transplant?

    abstract::The main cause of illness and death after the first year of heart transplantation is vasculopathy of the cardiac allograft, probably initiated by early immunological and non-immunological endothelial damage. The incidence of multiple episodes of grade 3A rejection 6 months after primary heart transplantation was lower...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.13.2.161

    authors: Doggrell SA

    更新日期:2004-02-01 00:00:00

  • Polo-like kinases in AML.

    abstract::New therapies targeting critical elements of the cell cycle open novel and attractive avenues for the treatment of cancer patients. At present, the number of clinical trials that are registered with the European Organization for Research and Treatment of Cancer (EORTC) and with the US National Cancer Institute, which ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 社论

    doi:10.1517/13543784.2012.691163

    authors: Berg T,Bug G,Ottmann OG,Strebhardt K

    更新日期:2012-08-01 00:00:00

  • Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trials.

    abstract:INTRODUCTION:Current treatment for polycythemia vera (PV) is limited and primarily targets thrombosis risk. Agents targeting distinct mechanisms of action within myeloproliferation are undergoing clinical evaluation to optimize efficacy, improve tolerance and augment long term disease complications. AREA COVERED:This ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2020.1782886

    authors: Padrnos L,Mesa R

    更新日期:2020-08-01 00:00:00

  • Novel therapeutic strategies targeting vascular endothelium in essential hypertension.

    abstract:IMPORTANCE OF THE FIELD:Several studies have demonstrated the high prevalence of hypertension and the crucial role of the association between endothelial function and hypertension. Thus, in depth investigation of the pathophysiological mechanisms linking endothelial dysfunction and hypertension, as well as evaluation o...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2010.522989

    authors: Tousoulis D,Papageorgiou N,Androulakis E,Paroutoglou K,Stefanadis C

    更新日期:2010-11-01 00:00:00

  • Antisense approach for the treatment of cytomegalovirus infection.

    abstract::Human cytomegalovirus (HCMV) is the most common viral opportunistic infection in patients suffering with acquired immunodeficiency virus (AIDS). HCMV is a systemic infection that may infect several sites in the body, including the retina, gastrointestinal tract, lungs, liver, and central nervous system. Retinitis is t...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.9.1157

    authors: Temsamani J,Pari GS,Guinot P

    更新日期:1997-09-01 00:00:00